Clinical and Pharmacological Aspects of Heptral in the Treatment of Non-alcoholic Steatohepatitis
The study included 50 patients with NASH. Among them were 15 men and 35 women. Initially all patients had abdominal type obesity.
Overweight body mass was diagnosed in 5 patients, 5 – I degree obesity, 8 – II degree, 7 – degree III and IV. Heptral is a pharmaceutical
preparation with positive influence on the main pathogenetic links of steatohepatitis. Including Heptral in the complex therapy of patients with
non-alcoholic steatohepatitis decreased the activity of enzymes of cytolysis, significantly improved the lipid peroxidation and hormonal status
indices in comparison with the basic therapy. Heptral also improved patients’ quality of life.